Cargando…

Gene Therapy and Chronic Pain

Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cope, Doris K., Lariviere, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917261/
https://www.ncbi.nlm.nih.gov/pubmed/16951899
http://dx.doi.org/10.1100/tsw.2006.197
_version_ 1783317168942743552
author Cope, Doris K.
Lariviere, William R.
author_facet Cope, Doris K.
Lariviere, William R.
author_sort Cope, Doris K.
collection PubMed
description Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column stimulation and intrathecal drug delivery systems, are second-line therapies. However, for refractory and severe pain, which is not adequately controlled by other modes of therapy, new emerging options, including molecular or gene therapy, may become more widely utilized as experimental results are translated into clinical options.
format Online
Article
Text
id pubmed-5917261
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher TheScientificWorldJOURNAL
record_format MEDLINE/PubMed
spelling pubmed-59172612018-06-03 Gene Therapy and Chronic Pain Cope, Doris K. Lariviere, William R. ScientificWorldJournal Review Article Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column stimulation and intrathecal drug delivery systems, are second-line therapies. However, for refractory and severe pain, which is not adequately controlled by other modes of therapy, new emerging options, including molecular or gene therapy, may become more widely utilized as experimental results are translated into clinical options. TheScientificWorldJOURNAL 2006-08-31 /pmc/articles/PMC5917261/ /pubmed/16951899 http://dx.doi.org/10.1100/tsw.2006.197 Text en Copyright © 2006 Doris K. Cope and William R. Lariviere. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Cope, Doris K.
Lariviere, William R.
Gene Therapy and Chronic Pain
title Gene Therapy and Chronic Pain
title_full Gene Therapy and Chronic Pain
title_fullStr Gene Therapy and Chronic Pain
title_full_unstemmed Gene Therapy and Chronic Pain
title_short Gene Therapy and Chronic Pain
title_sort gene therapy and chronic pain
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917261/
https://www.ncbi.nlm.nih.gov/pubmed/16951899
http://dx.doi.org/10.1100/tsw.2006.197
work_keys_str_mv AT copedorisk genetherapyandchronicpain
AT larivierewilliamr genetherapyandchronicpain